CMV Disease Recruiting Phase 3 Trials for Valganciclovir (DB01610)

IndicationStatusPhase
DBCOND0032050 (CMV Disease)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03443869Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)Prevention